Phaseline

Companies › Novaliq

Novaliq: clinical trials, targets and expected readouts

1 active drug program in 26 registered trials: 12 Phase 2, 10 Phase 4, 3 Phase 1, 1 Phase 3; Neurology, Cardiovascular, Gastroenterology, Genitourinary.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tacrolimus (NOV05)
FK506-binding protein 1A inhibitor
FKBP1APhase 2Non-infectious Anterior Uveitis; Kidney Transplantation; Kidney Disease, End-Stage; Renal Transplant Recipients …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03266393Tacrolimus (NOV05)Phase 4Kidney TransplantationGenitourinaryMar 2023
NCT04665310Tacrolimus (NOV05)Phase 4Kidney Disease, End-StageGenitourinaryJul 2025
NCT07285070Tacrolimus (NOV05)Phase 2Non-infectious Anterior UveitisInfectious diseaseOct 2026
NCT03797196Tacrolimus (NOV05)Phase 4Renal Transplant RecipientsGenitourinaryDec 2026
NCT03841097Tacrolimus (NOV05)Phase 4Kidney Transplant; ComplicationsGenitourinaryDec 2026
NCT05242315Tacrolimus (NOV05)Phase 4Liver Transplant; ComplicationsCardiovascularDec 2026
NCT05089604Tacrolimus (NOV05)Phase 4Liver TransplantationOtherDec 2026
NCT06701825Tacrolimus (NOV05)Phase 4Kidney Disease, ChronicGenitourinaryDec 2026
NCT01804634Tacrolimus (NOV05)Phase 2Refractory and/or Relapsed Metastatic Solid TumorsOncologyJan 2027
NCT05621759Tacrolimus (NOV05)Phase 2Graft Vs Host DiseaseImmunologyJan 2027
NCT03321656Tacrolimus (NOV05)Phase 2End Stage Renal DiseaseGenitourinaryMar 2027
NCT06751992Tacrolimus (NOV05)Phase 4Kidney Transplant RecipientsGenitourinaryMay 2027
NCT06828796Tacrolimus (NOV05)Phase 2Hematologic Disease and DisordersHematologyJun 2027
NCT06529536Tacrolimus (NOV05)Phase 4Solid Organ TransplantOtherAug 2027
NCT03816332Tacrolimus (NOV05)Phase 1Clinical Stage III Cutaneous Melanoma AJCC v8OncologySep 2027
NCT06807606Tacrolimus (NOV05)Phase 2Hematologic MalignanciesOncologyNov 2027
NCT03769298Tacrolimus (NOV05)Phase 2Kidney Pancreas TransplantationGastroenterologyDec 2027
NCT06591884Tacrolimus (NOV05)Phase 1Oral Erosive Lichen PlanusImmunologyDec 2027
NCT07302776Tacrolimus (NOV05)Phase 1GVHDOncologyFeb 2028
NCT00882895Tacrolimus (NOV05)Phase 2Lymphoma, Non-HodgkinOncologyJun 2028
NCT06235892Tacrolimus (NOV05)Phase 3Organ GraftsOtherJun 2028
NCT06268769Tacrolimus (NOV05)Phase 4ImmunosuppressionOtherNov 2028
NCT03970096Tacrolimus (NOV05)Phase 2Acute LeukemiaOncologyDec 2028
NCT04302870Tacrolimus (NOV05)Phase 2Motor Neuron Disease, Amyotrophic Lateral SclerosisNeurologyDec 2030
NCT05027945Tacrolimus (NOV05)Phase 2ImmunodeficiencyHematologyJul 2031
NCT05031897Tacrolimus (NOV05)Phase 2Acute Lymphoblastic LeukemiaOncologyApr 2032

Targets

FKBP1A (1)

Companies with the same targets

Eisai CSPC ZhongQi Pharmaceutical Technology Restorbio Novartis Rapamycin Holdings AgelessRx Palvella Therapeutics Jiangsu Simcere Pharmaceutical Aadi Bioscience Eyestem Research

Companies built like this

Aadi Bioscience Mercator MedSystems Ascension Health F2G Rapamycin Holdings

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.